User profiles for NJ Andrews
 | Nick AndrewsUK Health Security Agency Verified email at ukhsa.gov.uk Cited by 54934 |
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
…, ASV Stuart, M Greenland, PK Aley, NJ Andrews… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
Effect of vaccination on household transmission of SARS-CoV-2 in England
RJ Harris, JA Hall, A Zaidi, NJ Andrews… - … England Journal of …, 2021 - Mass Medical Soc
Vaccination and Household Transmission of SARS-CoV-2 In this study involving household
contacts of persons with laboratory-confirmed Covid-19, the risk of household transmission …
contacts of persons with laboratory-confirmed Covid-19, the risk of household transmission …
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
… EB Kaczmarski, NJ Andrews, and ME Ramsay have received funding from vaccine
manufacturers to attend conferences and meetings. CL Trotter has no conflicts of interest to declare. …
manufacturers to attend conferences and meetings. CL Trotter has no conflicts of interest to declare. …
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
Background The seven-valent pneumococcal conjugate vaccine (PCV7) has reduced
vaccine-type (VT) invasive pneumococcal disease but increases in non-vaccine-type (NVT) …
vaccine-type (VT) invasive pneumococcal disease but increases in non-vaccine-type (NVT) …
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK …
…, RH Shaw, X Liu, M Greenland, PK Aley, NJ Andrews… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
[HTML][HTML] Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an …
Background The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key
serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7), …
serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7), …
Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox
We present data to confirm that exposure to varicella boosts immunity to herpes-zoster. We
show that exposure to varicella is greater in adults living with children and that this exposure …
show that exposure to varicella is greater in adults living with children and that this exposure …
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis
Background In May, 2021, the delta (B.1.617.2) SARS-CoV-2 variant became dominant in the
UK, superseded by the omicron (B.1.1.529) variant in December, 2021. The delta variant is …
UK, superseded by the omicron (B.1.1.529) variant in December, 2021. The delta variant is …
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity
…, R Urwin, SJ Gray, NJ Andrews… - The Journal of …, 2008 - academic.oup.com
Background. In 1999, meningococcal serogroup C conjugate (MCC) vaccines were introduced
in the United Kingdom for those under 19 years of age. The impact of this intervention on …
in the United Kingdom for those under 19 years of age. The impact of this intervention on …
Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study
NJ Andrews, PA Waight, P Burbidge… - The Lancet infectious …, 2014 - thelancet.com
Background Efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) was
inferred before licensure from an aggregate correlate of protection established for the seven-valent …
inferred before licensure from an aggregate correlate of protection established for the seven-valent …
